80 related articles for article (PubMed ID: 8821955)
1. Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulation.
Kallakury BV; Figge J; Leibovich B; Hwang J; Rifkin M; Kaufman R; Figge HL; Nazeer T; Ross JS
Mod Pathol; 1996 Jan; 9(1):41-7. PubMed ID: 8821955
[TBL] [Abstract][Full Text] [Related]
2. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
3. Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.
Bellido M; Capello D; Altés A; Estivill C; Gaidano G; Pujol R; Bordes R; Baiget M; Saglio G; Sierra J; Nomdedéu JF
Haematologica; 2002 Sep; 87(9):908-17. PubMed ID: 12217802
[TBL] [Abstract][Full Text] [Related]
4. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
7. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
8. Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.
Furihata M; Sonobe H; Ohtsuki Y; Yamashita M; Morioka M; Yamamoto A; Terao N; Kuwahara M; Fujisaki N
J Pathol; 1996 Feb; 178(2):133-9. PubMed ID: 8683378
[TBL] [Abstract][Full Text] [Related]
9. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.
Sinicrope FA; Evans DB; Leach SD; Cleary KR; Fenoglio CJ; Lee JJ; Abbruzzese JL
Clin Cancer Res; 1996 Dec; 2(12):2015-22. PubMed ID: 9816161
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
[TBL] [Abstract][Full Text] [Related]
12. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2.
Nagao T; Sugano I; Ishida Y; Hasegawa M; Matsuzaki O; Konno A; Kondo Y; Nagao K
Cancer; 1998 Feb; 82(3):439-47. PubMed ID: 9452259
[TBL] [Abstract][Full Text] [Related]
13. p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma.
Hughes JH; Cohen MB; Robinson RA
Mod Pathol; 1995 Jun; 8(5):462-6. PubMed ID: 7675761
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy.
Rakozy C; Grignon DJ; Sarkar FH; Sakr WA; Littrup P; Forman J
Mod Pathol; 1998 Sep; 11(9):892-9. PubMed ID: 9758370
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
17. Significantly different bcl-2 expression profiles in gastric and non-gastric primary extranodal high-grade B-cell lymphomas.
Cogliatti SB; Griesser H; Peng H; Du MQ; Isaacson PG; Zimmermann DR; Maibach RC; Schmid U
J Pathol; 2000 Dec; 192(4):470-8. PubMed ID: 11113864
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
19. bcl-1 gene rearrangements in mantle cell lymphoma: a comprehensive analysis of 118 cases, including B-5-fixed tissue, by polymerase chain reaction and Southern transfer analysis.
Chibbar R; Leung K; McCormick S; Ritzkalla K; Strickler J; Staggs R; Poppema S; Brunning RD; McGlennen RC
Mod Pathol; 1998 Nov; 11(11):1089-97. PubMed ID: 9831207
[TBL] [Abstract][Full Text] [Related]
20. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study.
Briasoulis E; Tsokos M; Fountzilas G; Bafaloukos D; Kosmidis P; Samantas E; Skarlos D; Nicolaides C; Pavlidis N
Anticancer Res; 1998; 18(3B):1907-14. PubMed ID: 9677443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
